A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 57, Issue , 2015, Pages 11-16

  Eyre, Harris A ^a,b,c   Air, Tracy ^a   Proctor, Simon ^a   Rositano, Sebastian ^a   Baune, Bernhard T ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JAMES COOK UNIVERSITY   (Australia)

Author keywords

Anti inflammatory; Clinical trial; Depression; Immune; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESCITALOPRAM; FLUOXETINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADJUVANT THERAPY; ARTICLE; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; GERIATRIC DEPRESSION SCALE; HAMILTON SCALE; HUMAN; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; STUDY DESIGN; SYSTEMATIC REVIEW; PSYCHOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DEPRESSION; HUMANS;

EID: 84908519046     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.10.003     Document Type: Article

References (53)

1. Abbasi S.H., Hosseini F., Modabbernia A., Ashrafi M., Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 2012, 141:308-314.
2. Aid S., Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 2011, 93:46-51.
3. Aid S., Langenbach R., Bosetti F. Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation 2008, 5:17.
4. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009, 26:607-611.
5. Almeida O.P., Alfonso H., Jamrozik K., Hankey G.J., Flicker L. Aspirin use, depression, and cognitive impairment in later life: the health in men study. J Am Geriatr Soc 2010, 58:990-992.
6. Almeida O.P., Flicker L., Yeap B.B., Alfonso H., McCaul K., Hankey G.J. Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl Psychiatry 2012, 2:e151.
7. Anderson I.M., Ferrier I.N., Baldwin R.C., Cowen P.J., Howard L., Lewis G., et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008, 22:343-396.
8. Baune B.T., Smith E., Reppermund S., Air T., Samaras K., Lux O., et al. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. Psychoneuroendocrinology 2012, 37:1521-1530.
9. Berk M., Dean O., Drexhage H., McNeil J.J., Moylan S., O'Neil A., et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 2013, 11:74.
10. Choi S.H., Aid S., Choi U., Bosetti F. Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain. Pharmacogenomics J 2010, 10:448-457.
11. Collantes-Estevez E., Fernandez-Perez C. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Curr Med Res Opin 2003, 19:402-410.
12. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
13. Davis A., Gilhooley M., Agius M. Using non-steroidal anti-inflammatory drugs in the treatment of depression. Psychiatr Danub 2010, 22(Suppl. 1):S49-S52.
14. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
15. Eyre H., Baune B.T. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology 2012, 37:1397-1416.
16. Fields C., Drye L., Vaidya V., Lyketsos C. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry 2011, 20(6):505-513.
17. Fond G., Hamdani N., Kapczinski F., Boukouaci W., Drancourt N., Dargel A., et al. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand 2013, 129(3):163-179.
18. Galecki P., Florkowski A., Bienkiewicz M., Szemraj J. Functional polymorphism of cyclooxygenase-2 gene (G-765C) in depressive patients. Neuropsychobiology 2010, 62:116-120.
19. Galecki P., Galecka E., Maes M., Chamielec M., Orzechowska A., Bobinska K., et al. The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 2012, 138:360-366.
20. Gallagher P.J., Castro V., Fava M., Weilburg J.B., Murphy S.N., Gainer V.S., et al. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 2012, 169:1065-1072.
21. Goodwin G.M. Consensus Group of the British Association for P. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009, 23:346-388.
22. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
23. Hashemian F., Majd M., Hosseini S.M., Sharifi A., Panahi M.V.S., Bigdeli O. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naïve women with major depression. Bull Clin Psychopharmacol 2011, 21:S183-S184.
24. Holtzheimer P.E., Meeks T.W., Kelley M.E., Mufti M., Young R., McWhorter K., et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry 2008, 23:625-631.
25. Iyengar R.L., Gandhi S., Aneja A., Thorpe K., Razzouk L., Greenberg J., et al. NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med 2013, 126:1017:e11-e18.
26. Jones K.A., Thomsen C. The role of the innate immune system in psychiatric disorders. Mol Cell Neurosci 2013, 53:52-62.
27. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36:764-785.
28. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
29. Licinio J. Translational psychiatry: leading the transition from the cesspool of devastation to a place where the grass is really greener. Transl Psychiatry 2011, 1:e1.
30. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999, 461:25-46.
31. Maes M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis 2012, 27:405-413.
32. Mendlewicz J., Kriwin P., Oswald P., Souery D., Alboni S., Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006, 21:227-231.
33. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
34. Moylan S., Maes M., Wray N.R., Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2012, 18(5):595-606.
35. Muller N. The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr Danub 2013, 25:292-298.
36. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11:680-684.
37. Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
38. Musil R., Schwarz M.J., Riedel M., Dehning S., Cerovecki A., Spellmann I., et al. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression-no influence of celecoxib treatment. J Affect Disord 2011, 134:217-225.
39. Na K.S., Lee K.J., Lee J.S., Cho Y.S., Jung H.Y. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013, 48C:79-85.
40. Nery F.G., Monkul E.S., Hatch J.P., Fonseca M., Zunta-Soares G.B., Frey B.N., et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008, 23:87-94.
41. Pasco J.A., Jacka F.N., Williams L.J., Henry M.J., Nicholson G.C., Kotowicz M.A., et al. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 2010, 79:323-325.
42. Powell T.R., McGuffin P., D'Souza U.M., Cohen-Woods S., Hosang G.M., Martin C., et al. Putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients. PLoS One 2014, 9:e91076.
43. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41.
44. Rethorst C.D., Toups M.S., Greer T.L., Nakonezny P.A., Carmody T.J., Grannemann B.D., et al. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry 2013, 18:1119-1124.
45. Rieckmann N., Burg M.M., Kronish I.M., Chaplin W.F., Schwartz J.E., Davidson K.W. Aspirin adherence, depression and one-year prognosis after acute coronary syndrome. Psychother Psychosom 2011, 80:316-318.
46. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
47. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354:1231-1242.
48. Shelton R.C. Does concomitant use of NSAIDs reduce the effectiveness of antidepressants?. Am J Psychiatry 2012, 169:1012-1015.
49. Solomon D.H. COX-2 selective inhibitors: adverse cardiovascular effects 2014, UpToDate. http://www.uptodate.com/, Wolters Kluwer Health. D.E. Furst, C.P. Cannon (Eds.).
50. Solomon D.H. Nonselective NSAIDs: adverse cardiovascular effects 2014, UpToDate. ww.uptodate.com, Wolters Kluwer Health. D.E. Furst, C.P. Cannon (Eds.).
51. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
52. Uher R., Carver S., Power R.A., Mors O., Maier W., Rietschel M., et al. Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychol Med 2012, 1-9.
53. Warner-Schmidt J.L., Vanover K.E., Chen E.Y., Marshall J.J., Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 2011, 108:9262-9267.